Active Biotech AB has reached a manufacturing agreement with Famar Health Care Services Madrid SAU, a European provider of pharmaceutical manufacturing and development services.
Laquinimod, an orally administered small molecule has primarily been developed as a potential treatment of neurodegenerative diseases such as multiple sclerosis (MS) and Huntington's disease (HD).